A Phase II Trial of ACR-368 and Low Dose Gemcitabine for Head and Neck Squamous Cell Carcinoma
Phase 2
43
about 3.9 years
18+
1 site in FL
What this study is about
This trial is testing a treatment combination of ACR-368 and low dose gemcitabine in people with head and neck squamous cell carcinoma. Participants will receive the drugs every 2 weeks until their cancer worsens.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ACR-368
- 2.Take Gemcitabine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
gemcitabine
injection (Injection)
Primary: Overall Response Rate: Cohort A, Overall Response Rate: Cohort B
Secondary: Duration of response (DOR), Overall Survival (OS), Progression Free Survival (PFS), Safety and Tolerability
Oncology